Compounds > 7-hydroxy-2-n,n-dipropylaminotetralin
Page last updated: 2024-10-21

7-hydroxy-2-n,n-dipropylaminotetralin and Glioma

7-hydroxy-2-n,n-dipropylaminotetralin has been researched along with Glioma in 1 studies

7-hydroxy-2-N,N-dipropylaminotetralin: RN given refers to cpd without isomeric designation

Glioma: Benign and malignant central nervous system neoplasms derived from glial cells (i.e., astrocytes, oligodendrocytes, and ependymocytes). Astrocytes may give rise to astrocytomas (ASTROCYTOMA) or glioblastoma multiforme (see GLIOBLASTOMA). Oligodendrocytes give rise to oligodendrogliomas (OLIGODENDROGLIOMA) and ependymocytes may undergo transformation to become EPENDYMOMA; CHOROID PLEXUS NEOPLASMS; or colloid cysts of the third ventricle. (From Escourolle et al., Manual of Basic Neuropathology, 2nd ed, p21)

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's1 (100.00)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Watts, VJ1
Lawler, CP1
Knoerzer, T1
Mayleben, MA1
Neve, KA1
Nichols, DE1
Mailman, RB1

Other Studies

1 other study available for 7-hydroxy-2-n,n-dipropylaminotetralin and Glioma

ArticleYear
Hexahydrobenzo[a]phenanthridines: novel dopamine D3 receptor ligands.
    European journal of pharmacology, 1993, Aug-03, Volume: 239, Issue:1-3

    Topics: Animals; Binding Sites; Glioma; Phenanthridines; Rats; Receptors, Dopamine; Receptors, Dopamine D2;

1993